NEW YORK (GenomeWeb) – Danaher today initiated its earning outlook for 2019, saying EPS is anticipated to be in the range of $4.02 to $4.12.

On a non-GAAP basis, EPS is expected to be in the range of $4.75 to $4.85, which assumes non-GAAP core revenue growth of about 4 percent. The Washington-based conglomerate, which owns Cepheid, Sciex, Beckman Coulter, and other life sciences and diagnostics companies, issued its guidance ahead of its annual investor and analyst meeting being held today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.